Recorlev (levoketoconazole), Strongbridge Biopharma's oral investigational therapy for endogenous Cushing's syndrome, resulted in sustained improvements in cortisol and glycemic control in patients with Cushing...
This article was originally published here
Endocr Connect. 2021 March 1st: EC-20-0567.R2. doi: 10.1530 / EC-20-0567. Online before printing.
ABSTRACT
OBJECTIVE: COVID-19 in people...